HCM
RVPH

Heights Capital Management’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Heights Capital Management’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-91,495
Closed -$697K – 200
2025
Q2 		$697K Buy
+91,495
New +$1.42M 0.19% 61

Other funds holding RVPH

DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
ECM
EMC Capital Management Houston, Texas $253M AUM

Heights Capital Management's RVPH Position: Q3 2025 in Review

Heights Capital Management sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q3 2025, closing a stake of 91,495 shares — an estimated $697K sold.

Heights Capital Management first reported a position in RVPH in Q2 2025 and held it in 1 quarter. The position peaked at $697K in Q2 2025. 42 funds tracked by Wall St. Rank hold RVPH as of Q3 2025.

  • Heights Capital Management reported no remaining REVIVA PHARMA HLDGS INC position as of Q3 2025 after selling out during the quarter.
  • Heights Capital Management sold 91,495 REVIVA PHARMA HLDGS INC shares in Q3 2025, an estimated $697K.
  • Heights Capital Management first reported a position in REVIVA PHARMA HLDGS INC in Q2 2025 and held it in 1 quarter.
  • Heights Capital Management's REVIVA PHARMA HLDGS INC position peaked at $697K in Q2 2025.
  • 42 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q3 2025.

Based on Heights Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.